Tagged with ase

Sweden Grifols is a pioneer in plasma science that develops plasma into essential medicines used to treat rare, chronic and life-threatening conditions. Eric Björnestål, general manager for the Nordic region, explains how the company is leveraging its knowledge of the public tender process to continue to grow in the region, highlights…

Thailand Riaz Buksh, general manager of Bayer’s Pharmaceuticals Division in Thailand, Cambodia, Myanmar, and Laos, highlights the importance of the mission “Science for a Better Life” and innovation in the affiliate, as well as the vision of Bayer in driving transformative partnerships with government and medical stakeholders.   A collaboration of…

Sweden Olav Fromm, managing director of Chiesi Nordics, explains the deep roots of Chiesi in Sweden, where its blockbuster drug, a surfactant for treating neonatal babies, was developed. He also touches upon the strategic importance of the region to Chiesi, with the recent creation of a fully-fledged Nordic subsidiary, which will…

Sweden Johan Wäborg, General Manager Nordic countries at Actelion, shares the importance of Sweden for the group due to its world-class healthcare system and community of experts as well as its national quality and health registries which make the country an ideal environment for early launches and follow-up of treatment outcomes.…

Spain Though still one of the younger and lesser-known outfits inhabiting the European drug development landscape, Irish-headquartered rare disease specialist, Jazz pharma has been making tremendous headway in the onco-haematology and sleep disorder spaces and the Spanish affiliate is absolutely no exception.   We blend the lessons of art with our…

Puerto Rico David Foster, president and co-founder of Isla Pharmaceuticals, explains the rationale behind selecting Puerto Rico as a base for the company, which aims to develop treatments for mosquito-borne disease. He highlights Isla Pharmaceuticals’ unique approach of tackling diseases like Dengue fever and reveals plans for conducting follow-up clinical trials in…

USA PhRMA’s Anne McDonald Pritchett PhD highlights the remarkable development of cell and gene therapies in recent years and the three ways in which the US healthcare system can better accommodate them: creating manufacturing systems that take treatment timelines into account, a health system that values treatments based on patient outcomes,…

Thailand Thailand has experienced a steady decline in infectious disease rates in the last generation thanks to the country’s commitment to life sciences research. The executive vice president of the National Science and Technology Development Agency elaborates on Thailand’s research on infectious diseases and how collaboration fuels further progress.    We…

Thailand Dr Kumthorn Malathum, president of the Infectious Disease Association of Thailand, shares his insight on the issue of infectious disease in the country and the need to develop collaboration in order to tackle these infections.   Due to the country’s climate and people’s way of life, infectious diseases are a…

Taiwan Dr Hardy Chan shares the story of how he came out of retirement to lead Allianz Pharmascience; an up-and-coming biotech which aims to meet the unmet medical needs of rare disease patients, particularly in Asia. Dr Chan delves deep into the innovative science behind the company’s pipeline and shares the…

Sweden Amicus Therapeutics is a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases. Mattias Bankel, Head of Nordics and Baltics, shares his journey of establishing and developing Amicus’s presence in Sweden and other Nordic countries, furthermore his commitment to ensure that…

Spain Stefanie Granado, director general of Takeda Iberia recounts the opportunities available for Takeda in Spain following its acquisition of Shire. She also discusses Takeda’s local acquisition of TiGenix, handing Takeda stem cell production capabilities, and how this makes Spain a key market and hub for the company.   We continue…